![45_pipeline_0](https://www.hivplusmag.com/media-library/45-pipeline-0.jpg?id=32677842&width=1200&height=800)
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
There are more than seven dozen anti-HIV drug candidates in various stages of testing. While some will be unsuccessful, the potential for newly developed medications as well as medication classes is better than ever before in the almost 25 years of the AIDS pandemic. The two main new drug classes in development are integrase inhibitors and maturation inhibitors. Integrase inhibitors interfere at the viral replication step in which HIV's genetic information is inserted into the host cell's DNA, thereby enabling the cell to start making copies of the virus. Integrase inhibitors target and disable HIV's integrase enzyme, which plays a key role in this replication step. Maturation inhibitors interfere with the final stages of HIV replication, in which viral copies are assembled and exit an infected cell. These drugs would prevent the virus from properly assembling, from forming a protective outer coat, or from emerging--also known as budding--from human cells. Below is a list of anti-HIV drugs in development, listed alphabetically in respective drug categories. Each listing also includes the drug's stage of development and company that is working on the medication. Entry Inhibitors AMD-070 (CXCR4 blocker); phase II; Anormed. AMD-887 (CCR5 blocker); preclinical; Anormed. AMD3100 (CXCR4 blocker); phase I; Anormed. Betulinic acid derivatives (entry, maturation inhibitors); preclinical; University of North Carolina-Duke-Vanderbilt. BMS-043; phase I/II; Bristol-Myers Squibb. BMS-378806 (gp120 blocker); phase I; Bristol-Myers Squibb. CCR5mAb004 (CCR5 blocker); preclinical; Human Genome Sciences. D5 (artificial gp41 blocker); preclinical; Merck. GBV-C (virus increases chemokines,including CCR5 blockers); preclinical; University of Iowa. GSK-873140 (CCR5 blocker); phase II; GlaxoSmithKline. IC9564; preclinical; Duke University. KRH-2731 (CXCR4 blocker); preclinical; Kureha. Maraviroc/UK-427 (CCR5 blocker); phase II; Pfizer. MDX-010; phase I; Medarex. NB-2 (gp41 blocker); preclinical; Shibo-Kumar. NB-64 (gp41 blocker); preclinical; Shibo-Kumar. PRO-140 (monoclonal antibody); preclinical; Progenics. PRO-542 (attachment inhibitor); phase II; Progenics. RC-112; preclinical; CDC's AIDS, STD, and TB Laboratory Research. Retrocyclin-1; preclinical; CDC's AIDS, STD, and TB Laboratory Research. SP-01 A; phase I/II; Samaritan. TAK-652 (CCR5 blocker); preclinical; Takeda. TNX-355 (monoclonal antibody); phase I/II; Tanox-Biogen. UMIST; preclinical; Genetic Innovation. Vicriviroc/SCH-D (CCR5 blocker); phase II; Schering Plough. Integrase Inhibitors Carbazole derivative; preclinical; Japan's National Institute of Infectious Diseases. GSK-810871; preclinical; GlaxoSmithKline. Indolicidin; preclinical; National Cancer Institute. JTK-303; phase I/II; Gilead-Japan Tobacco. L-810810; phase I; Merck. Styrylquinoline derivatives; preclinical; BioAlliance Pharma. V-165; preclinical; Belgium's Rega Institute. Maturation Inhibitors Betulinic acid derivatives (entry, maturation inhibitors); preclinical; University of North Carolina-Duke-Vanderbilt. Chloroquinine; preclinical; Catholic University of Rome. enJS56A1; preclinical; University of Georgia. PA-457 (capsid inhibitor); phase II; Vitex. Nonnucleoside Reverse Transcriptase Inhibitors BILR 355 BS; preclinical; Boehringer-Ingelheim. Calanolide A; phase II; Advanced Life Sciences. Capravirine; phase II; Pfizer. DOT (dioxolane thymidine); phase I; University of Georgia. GSK-695634; phase I; GlaxoSmithKline. KP1212; phase I; Koronis. MIV-150; phase II; Medivir. MIV-170; preclinical; Medivir. NVP C-8 derivatives; preclinical; Boehringer-Ingelheim. Oligodeoxi nucleotides; preclinical; University of Zurich. S-DABO derivatives; preclinical; China's Fudan University. SMP-610; preclinical; Advanced Life Sciences. SMP-717; preclinical; Advanced Life Sciences. Thiazol derivatives; preclinical; Japan's Institute for Virus Research. TMC-125 (etravirine); phase II; Tibotec-Johnson and Johnson. TMC-278 (diarylpyrimidine or DAPY); phase II; Tibotec. Tricyclic NNRTI; preclinical; Bristol-Myers Squibb. Nucleoside Reverse Transcriptase Inhibitors Alovudine (MIV-310); phase II; Medivir-Boehringer-Ingelheim. Amdoxovir (DAPD); phase II; RFS Pharm. BPH-218; preclinical; University of Pittsburgh. Compound X; preclinical; Tibotec. Dinucleoside polyphosphates; preclinical; University of Miami. Elvucitabine (ACH-126); phase II; Achillion. GSK-204937; phase I; GlaxoSmithKline. KMMP05; preclinical; National Cancer Institute. MIV-210; phase I/II; Medivir-GlaxoSmithKline. Racivir; phase I/II; Pharmasset. Reverset (D-D4FC); phase II; Pharmasset-Incyte. SPD-754; phase I/II; Avexa. Protease Inhibitors A-681799; preclinical; Abbott Laboratories. AG-1859; phase II; Pfizer. Aptivus (tipranavir); Approved by FDA on June 22; Boehringer-Ingelheim. GSK-640385 (VX-385); phase I/II; GlaxoSmithKline. PPL-100; preclinical; Procyon Biopharma. TMC-114; phase II; Tibotec-Johnson and Johnson. UIC02031; preclinical; Kumamoto University. Others ACH-CIC (capsid inhibitor complex); preclinical; Achillion. BAY 50-4798 (interleukin-2 selective agonist); phase I; Bayer. BL-1050 (regulatory protein inhibitor); preclinical; BioLine Rx. CDK inhibitor; preclinical; Gilead Sciences. CNI-1493 (rev inhibitor); preclinical; Heinrich Pette Institute. Curcumin/diferuloylmethane (tat inhibitor); preclinical; India's Jawaharlal Nehru Center. HGTV43 (gene regulation-editing inhibitor); phase I; Enzo. MDI-P (electrolyzed free radical); preclinical; Medical Discoveries. Mifepristone (glucocorticoid antagonist); phase I; University of Pittsburgh. Resveretrol (Egr1 gene activator); preclinical; National Cancer Institute. RSC-1838; preclinical; GlaxoSmithKline-Shionogi. RWJ67567 (p38 inhibitor); preclinical; University of Pennsylvania-Johnson and Johnson. siRNA molecule; preclinical; CombiMatrix. TRIM5-alpha (capsid inhibitor); preclinical; Dana Farber Cancer Institute-NAIAD. VRX496 (antisense lentiviral vector); phase I; VIRxSYS.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Before AIDS, gay artist Rex drew hot men on the prowl — then he disappeared
April 11 2024 3:15 PM
Diets that mimic fasting reverse aging: study
March 07 2024 5:28 PM
PrEP without a prescription now a reality in California
February 06 2024 8:37 PM
Injectable HIV treatment, prevention: Everything you need to know
March 26 2024 3:28 PM
8 dating tips for gay men from a gay therapist
March 21 2024 2:50 PM
Happy national foreskin day!
April 04 2024 1:45 PM
The science behind U=U has been liberating people with HIV for years
June 04 2024 3:31 PM
Scarlet fever: exploring our fascination with blood
March 13 2024 1:47 PM
On Anal Sex Day, crack up with The Bottom's Digest
April 18 2024 10:22 AM
Plus: Featured Video
Latest Stories
Activist and philanthropist Bruce Bastian dies at 76
June 26 2024 1:28 PM
Yes, HIV-positive people can safely breastfeed
June 26 2024 12:59 PM
Exclusive: We kiki with Q from 'RuPaul's Drag Race'
June 24 2024 11:37 AM
Court rules to keep PrEP coverage under Obamacare
June 21 2024 5:42 PM
In honor of Juneteenth 2024, meet The Normal Anomaly
June 19 2024 1:39 PM
What is Juneteenth?
June 19 2024 11:30 AM
As Pride party season begins, the CDC urges mpox vaccinations
May 16 2024 6:52 PM
Advocacy in action with AIDSWatch
May 09 2024 12:30 PM
The Talk: Thriving with HIV
May 08 2024 10:45 AM
The Talk: What HIV isn’t
May 07 2024 10:48 AM
The Talk: Finding balance with HIV
May 06 2024 10:51 AM
Justice Dept plans to reschedule marijuana as a lower-risk drug
May 03 2024 2:40 PM
The Talk: Starting your journey with HIV
May 03 2024 2:00 PM
Why is a mother’s mental health so important? A doctor explains
May 01 2024 1:38 PM
Walmart to close all of its health care clinics
April 30 2024 12:30 PM
Vampire facial spa infected several women with HIV
April 29 2024 7:26 PM